Interferon-β-1a (Avonex) 30 mcg and 60 mcg are equally effective in patients with relapsing multiple sclerosis:: results from the Cyprus study site of the European IFNβ-1a Dose Comparison Study

被引：0

作者：

Kkolou, E ^{[1
]}

Papacostas, S ^{[1
]}

Kyriallis, K ^{[1
]}

Toufexis, J ^{[1
]}

Pantzaris, M ^{[1
]}

机构：

[1] Cyprus Inst Neurol & Genet, Nicosia, Cyprus

来源：

MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S243 / S243

页数：1

共 50 条

[21] Factors associated with acceptance to intramuscular interferon β-1a in patients with multiple sclerosis: results from the ADOPTE study [J].

Mekies, C. ;

Coustans, M. ;

Bouree, S. ;

Bourhis, Y. ;

Nouet, S. ;

Debouverie, M. .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 :388-388

[22] Safety of adult doses of subcutaneous interferon-β-1a in children and adolescents with multiple sclerosis: results of the REPLAY study [J].

Ghezzi, A. ;

Pohl, D. ;

Banwell, B. ;

Krupp, L. B. ;

Boyko, A. ;

Meinel, M. ;

Lehr, L. ;

Moraga, M. Stam ;

Tenembaum, S. .

MULTIPLE SCLEROSIS JOURNAL, 2012, 18 :74-75

[23] Disability and impact profile in multiple sclerosis patients treated with high-dose interferon-β 1a [J].

Schluep, M ;

Bogousslavsky, J .

MULTIPLE SCLEROSIS, 2004, 10 (7032) :S252-S252

[24] ASA Study -: combination of interferon-β 1a, azathioprine and oral prednisone in remitting multiple sclerosis [J].

Horakova, D ;

Havrdova, E ;

Krasensky, J ;

Meluzinova, E ;

Dolezal, O ;

Vaneckova, M ;

Seidl, Z ;

Svobodnik, A .

MULTIPLE SCLEROSIS, 2004, 10 (7032) :S262-S263

[25] Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study [J].

Bayas, Antonios ;

Ouallet, Jean Christophe ;

Kallmann, Boris ;

Hupperts, Raymond ;

Fulda, Ulrich ;

Marhardt, Kurt .

EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (08) :1239-1250

[26] Subcutaneous interferon-β-1a in paediatric patients with multiple sclerosis: regional outcomes in an international retrospective study (REPLAY) [J].

Krupp, L. B. ;

Pohl, D. ;

Ghezzi, A. ;

Boyko, A. ;

Tenembaum, S. ;

Meinel, M. ;

Moraga, M. Stam ;

McIlroy, C. ;

Lehr, L. ;

Banwell, B. .

MULTIPLE SCLEROSIS JOURNAL, 2012, 18 :298-298

[27] Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis [J].

Sauri-Suarez, Sergio ;

Quinones-Aguilar, Sandra ;

Contreras-Marin, Arturo ;

Omar Ramiro-Guerrero, Erik ;

Zuniga-Garcia, David ;

Salinas-Vazquez, Leticia ;

Llamas-Lopez, Leonardo ;

Leon-Jimenez, Carolina ;

Garcia-Martell, Adriana ;

Gonzalez-Hernandez, Iliana ;

Chiquete, Erwin ;

Garcia, Silvia .

PLOS ONE, 2020, 15 (04)

[28] The PRISMS study. Interferon-β 1a (Rebif) in intermittent multiple sclerosis [Die PRISMS-studie. Interferon-β 1a (Rebif®) bei schubformiger multipler sklerose] [J].

Hartung H.-P. ;

Flachenecker P. ;

Weilbach F.X. ;

Rieckmann P. .

Der Nervenarzt, 1999, 70 (2) :182-185

[29] INTERFERON-β 1A, AN IMMUNOMODULATOR IN RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS. THE EFFECT ON PRO-INFLAMMATORY CYTOKINES [J].

Maier, Smaranda ;

Motataianu, Anca ;

Barcutean, Laura ;

Balint, Alina ;

Hutanu, Adina ;

Zoltan, Bajko ;

Stoian, Adina ;

Romaniuc, Andreea ;

Andone, Sebastian ;

Balasa, Rodica .

FARMACIA, 2020, 68 (01) :65-75

[30] 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a:: results of a preliminary study [J].

Sarchielli, P ;

Presciutti, O ;

Tarducci, R ;

Gobbi, G ;

Alberti, A ;

Pelliccioli, GP ;

Orlacchio, A ;

Gallai, V .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (02) :204-212

← 1 2 3 4 5 →